The predominant therapy for gliomatosis cerebri is [[surgical resection]]. Adjunctive [[chemotherapy]] and [[radiation]] may be required.<ref name="pmid21301914">{{cite journal| author=Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T| title=Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. | journal=Neurosurg Rev | year= 2010 | volume= 34 | issue= 2 | pages= 197-208 | pmid=21301914 | doi=10.1007/s10143-010-0306-1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21301914 }} </ref><ref name="pmid11708542">{{cite journal| author=Hejazi N, Witzmann A, Hergan K| title=Gliomatosis cerebri: intra vitam stereotactic determination in two cases and review of the literature. | journal=Br J Neurosurg | year= 2001 | volume= 15 | issue= 5 | pages= 396-401 | pmid=11708542 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11708542 }} </ref><ref name="pmid15277636">{{cite journal| author=Levin N, Gomori JM, Siegal T| title=Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. | journal=Neurology | year= 2004 | volume= 63 | issue= 2 | pages= 354-6 | pmid=15277636 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15277636 }} </ref><ref name="pmid14684203">{{cite journal| author=Lodi R, Setola E, Tonon C, Ambrosetto P, Franceschi E, Crinò L et al.| title=Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. | journal=Magn Reson Imaging | year= 2003 | volume= 21 | issue= 9 | pages= 1003-7 | pmid=14684203 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14684203 }} </ref><ref name="pmid15798516">{{cite journal| author=Sanson M, Napolitano M, Cartalat-Carel S, Taillibert S| title=[Gliomatosis cerebri]. | journal=Rev Neurol (Paris) | year= 2005 | volume= 161 | issue= 2 | pages= 173-81 | pmid=15798516 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15798516 }} </ref><ref name="pmid12325066">{{cite journal| author=Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB et al.| title=Gliomatosis cerebri: molecular pathology and clinical course. | journal=Ann Neurol | year= 2002 | volume= 52 | issue= 4 | pages= 390-9 | pmid=12325066 | doi=10.1002/ana.10297 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12325066 }} </ref><ref name="pmid7407756">{{cite journal| author=Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ et al.| title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. | journal=Cancer Treat Rep | year= 1980 | volume= 64 | issue= 2-3 | pages= 237-44 | pmid=7407756 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7407756 }} </ref><ref name="pmid24744992">{{cite journal| author=Qaddoumi I, Kocak M, Pai Panandiker AS, Armstrong GT, Wetmore C, Crawford JR et al.| title=Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. | journal=Front Oncol | year= 2014 | volume= 4 | issue= | pages= 67 | pmid=24744992 | doi=10.3389/fonc.2014.00067 | pmc=PMC3978340 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24744992 }} </ref><ref name="pmid8905746">{{cite journal| author=Kyritsis AP, Yung WK, Jaeckle KA, Bruner J, Gleason MJ, Ictech SE et al.| title=Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. | journal=Neurosurgery | year= 1996 | volume= 39 | issue= 5 | pages= 921-6 | pmid=8905746 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8905746 }} </ref> Supportive therapy for gliomatosis cerebri includes [[anticonvulsants]] and [[corticosteroids]].<ref name="pmid22740882">{{cite journal| author=Rajz GG, Nass D, Talianski E, Pfeffer R, Spiegelmann R, Cohen ZR| title=Presentation patterns and outcome of gliomatosis cerebri. | journal=Oncol Lett | year= 2012 | volume= 3 | issue= 1 | pages= 209-213 | pmid=22740882 | doi=10.3892/ol.2011.445 | pmc=PMC3362440 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22740882 }} </ref>
[[Radiotherapy]] and [[chemotherapy]] are recommended among all patients who develop gliomatosis cerebri. [[Temozolomide]] and [[PCV regimen|PCV 3 combination chemotherapy]] are the preferred drugs for the treatment of high-grade and low-grade gliomatosis cerebri, respectivel Supportive therapy for gliomatosis cerebri includes [[anticonvulsants]] and [[corticosteroids]].
==Medical Therapy==
==Medical Therapy==
The predominant therapy for gliomatosis cerebri is [[surgical resection]]. Adjunctive [[chemotherapy]] and [[radiation]] may be required.<ref name="pmid21301914">{{cite journal| author=Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T| title=Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. | journal=Neurosurg Rev | year= 2010 | volume= 34 | issue= 2 | pages= 197-208 | pmid=21301914 | doi=10.1007/s10143-010-0306-1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21301914 }} </ref><ref name="pmid11708542">{{cite journal| author=Hejazi N, Witzmann A, Hergan K| title=Gliomatosis cerebri: intra vitam stereotactic determination in two cases and review of the literature. | journal=Br J Neurosurg | year= 2001 | volume= 15 | issue= 5 | pages= 396-401 | pmid=11708542 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11708542 }} </ref><ref name="pmid15277636">{{cite journal| author=Levin N, Gomori JM, Siegal T| title=Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. | journal=Neurology | year= 2004 | volume= 63 | issue= 2 | pages= 354-6 | pmid=15277636 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15277636 }} </ref><ref name="pmid14684203">{{cite journal| author=Lodi R, Setola E, Tonon C, Ambrosetto P, Franceschi E, Crinò L et al.| title=Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. | journal=Magn Reson Imaging | year= 2003 | volume= 21 | issue= 9 | pages= 1003-7 | pmid=14684203 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14684203 }} </ref><ref name="pmid15798516">{{cite journal| author=Sanson M, Napolitano M, Cartalat-Carel S, Taillibert S| title=[Gliomatosis cerebri]. | journal=Rev Neurol (Paris) | year= 2005 | volume= 161 | issue= 2 | pages= 173-81 | pmid=15798516 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15798516 }} </ref><ref name="pmid12325066">{{cite journal| author=Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB et al.| title=Gliomatosis cerebri: molecular pathology and clinical course. | journal=Ann Neurol | year= 2002 | volume= 52 | issue= 4 | pages= 390-9 | pmid=12325066 | doi=10.1002/ana.10297 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12325066 }} </ref><ref name="pmid7407756">{{cite journal| author=Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ et al.| title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. | journal=Cancer Treat Rep | year= 1980 | volume= 64 | issue= 2-3 | pages= 237-44 | pmid=7407756 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7407756 }} </ref><ref name="pmid24744992">{{cite journal| author=Qaddoumi I, Kocak M, Pai Panandiker AS, Armstrong GT, Wetmore C, Crawford JR et al.| title=Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. | journal=Front Oncol | year= 2014 | volume= 4 | issue= | pages= 67 | pmid=24744992 | doi=10.3389/fonc.2014.00067 | pmc=PMC3978340 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24744992 }} </ref><ref name="pmid8905746">{{cite journal| author=Kyritsis AP, Yung WK, Jaeckle KA, Bruner J, Gleason MJ, Ictech SE et al.| title=Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. | journal=Neurosurgery | year= 1996 | volume= 39 | issue= 5 | pages= 921-6 | pmid=8905746 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8905746 }} </ref> Supportive therapy for gliomatosis cerebri includes [[anticonvulsants]] and [[corticosteroids]].<ref name="pmid22740882">{{cite journal| author=Rajz GG, Nass D, Talianski E, Pfeffer R, Spiegelmann R, Cohen ZR| title=Presentation patterns and outcome of gliomatosis cerebri. | journal=Oncol Lett | year= 2012 | volume= 3 | issue= 1 | pages= 209-213 | pmid=22740882 | doi=10.3892/ol.2011.445 | pmc=PMC3362440 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22740882 }} </ref>
The medical therapy of gliomatosis cerebri includes:
===1. Radiotherapy===
===1. Radiotherapy===
*[[Radiation|Post-operative radiotherapy]] is recommended among all patients who develop gliomatosis cerebri.<ref name="pmid21301914">{{cite journal| author=Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T| title=Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. | journal=Neurosurg Rev | year= 2010 | volume= 34 | issue= 2 | pages= 197-208 | pmid=21301914 | doi=10.1007/s10143-010-0306-1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21301914 }} </ref>
*[[Radiation|Post-operative radiotherapy]] is recommended among all patients who develop gliomatosis cerebri.<ref name="pmid21301914">{{cite journal| author=Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T| title=Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. | journal=Neurosurg Rev | year= 2010 | volume= 34 | issue= 2 | pages= 197-208 | pmid=21301914 | doi=10.1007/s10143-010-0306-1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21301914 }} </ref>
CCNU is administered on day 1, procarbazine is administered daily for 14 days beginning on day 8, and vincristine is administered on days 8 and 29 of each 6-week cycle of therapy.[7]
Other chemotherapeutic drugs that may be used for the treatment of gliomatosis cerebri include:[8][9][10]
Supportive therapy for gliomatosis cerebri includes anticonvulsants and corticosteroids, which focuses on relieving symptoms and improving the patient’s neurologic function.[2]